Afatinib in advanced refractory urothelial cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Urothelial Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Patients must have locally advanced or metastatic urothelial cancer that is not amenable to surgical treatment 2. Patients must have histologically or cytologically confirmed urothelial tract carcinoma. 3. All patients must have received a prior platinum-based chemotherapy regimen for treatment of urothelial cancer and must now be considered refractory to platinum-based chemotherapy.

You may not be eligible for this study if the following are true:

  • 1. Patients may not be receiving any other investigational agents. 2. Patients with untreated known brain etastases, or treated brain metastases that are clinically unstable. 3. Uncontrolled illness Including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study require ents.
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.